A PHARMACOECONOMIC EVALUATION OF ROMIPLOSTIM (NPLATE®) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN MEXICO

Author(s)

Arocho R1, Northridge K2, Rivera Hurtado R3, García Chávez J41Amgen, Inc., Barcelona, Spain, 2Outcomes Insights, Inc., Westlake Village, CA, USA, 3Amgen Mexico, Mexico City, Mexico, 4Mexican Institute for Social Security (IMSS), Mexico City, Mexico

OBJECTIVES: ITP is characterized by reduced platelet counts and increased risk of bleeding. Romiplostim, a first-in-class thrombopoietin mimetic, safely increases and sustains platelet counts in most adult patients with chronic ITP for as long as needed, while reducing the need for concurrent and emergency medications. We evaluated treatment costs per overall platelet response with romiplostim + concurrent treatment vs. placebo + concurrent treatment in chronic adult ITP, from a Public Mexican Healthcare perspective. METHODS: Overall response, defined as ≥ 4 weekly platelet responses (≥50x109/L ) from weeks 2 to 25, was derived from two randomized parallel trials with splenectomised and non-splenectomised patients over period of 24 weeks. All patients were allowed to enter on concurrent ITP medication (danazol, corticosteroids, azathioprine) and receive rescue medication (eg, intravenous immunoglobulin). Treatment costs included intervention, rescue medication and management of bleeding-related events during one year period. Unitary costs were obtained from the 2010 Official Price List of the Public Healthcare System in Mexico ($MXP). Mean treatment cost per response was calculated for splenectomized and non-splenectomized patients. RESULTS: Cost per response was lower for romiplostim compared to placebo. Overall response rates were 79% for romiplostim and 0% for placebo in splenectomized patients and 88% for romiplostim vs. 14% for placebo in non-splenectomized patients. Mean treatment costs were MXP$574,580 for romiplostim and MXP$301,218 for placebo in splenectomized patients and MXP$402,083 for romiplostim and MXP$180,692 for placebo in non-splenectomized patients. Cost per response were MXP$727,317 for romiplostim and infinite cost per response for placebo in splenectomized patients and MXP$456,912 for romiplostim and MXP$1,290,655 for placebo in non-splenectomized patients. The main cost-offsets were due to reduced immunoglobulin rescue use. CONCLUSIONS: Given the limited number of effective therapies in ITP, romiplostim demonstrates an important and cost-efficient option for both non-splenectomised and splenectomised patients for the Mexican Public Healthcare System.

Conference/Value in Health Info

2011-05, ISPOR 2011, Baltimore, MD, USA

Value in Health, Vol. 14, No. 3 (May 2011)

Code

PSY17

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×